Saturday 17 October 2026
Export BCDA’s income statement to Excel — free account
BioCardia, Inc.
BCDA Healthcare Biotechnology
BioCardia, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $477,000.00, up 722.4% from fiscal 2024. In the quarter to June 2026, EPS grew 67.5% and free cash flow fell 5.15%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.92
0.02
−2.13%
Follow BCDA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(317.47%) | (950.12%) | 601.31% | (1,803.19%) | |
| (137.58%) | (230.57%) | (400.98%) | (214.47%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(412.96%) | (2,603.80%) | 479.35% | (325.31%) | |
Average Days of Receivables |
— | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(1.17) | (1.12) | (0.69) | (0.63) | |
Free Cash Flow |
(7.38) | (7.44) | (7.49) | (7.57) | |
Capital Expenditures |
0.00 | (0.01) | (0.01) | (0.01) | |
| Other line items | |||||
Cash ROIC |
(93.20%) | (219.52%) | 7,881.05% | (111.08%) | |
Accounts Receivable Turnover |
— | 0.00 | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.86 | 0.90 | 0.96 | 1.03 | |
Depreciation/Fixed assets |
2.77 | 1.50 | 0.94 | 1.00 | |
Capex/Depreciation |
(0.11) | (0.33) | (0.67) | (0.69) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.17) | (1.12) | (0.69) | (0.63) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates